Prevalence and clinical implications of Epstein-Barr virus infection in de Novo diffuse large B-cell lymphoma in western countries

Clinical Cancer Research

Volumn 20, Issue 9, 2014, Pages 2338-2349

  Ok, Chi Young ^a   Li, Ling ^a   Xu Monette, Zijun Y ^a   Visco, Carlo ^k   Tzankov, Alexander ^m   Manyam, Ganiraju C ^a   Montes Moreno, Santiago ⁿ   Dybaer, Karen ^o   Chiu, April ^c   Orazi, Attilio ^d   Zu, Youli ^b   Bhagat, Govind ^e   Chen, Jiayu ^q   Richards, Kristy L ^f   Hsi, Eric D ^g   Choi, William W L ^r   Van Krieken, J Han ^s   Huh, Jooryung ^t   Ai, Weiyun ^h   Ponzoni, Maurilio ^l   Ferreri, Andrés J M ^l   Farnen, John P ⁱ   Møller, Michael B ^p   Bueso Ramos, Carlo E ^a   Miranda, Roberto N ^a   Winter, Jane N ^j   Piris, Miguel A ⁿ   Medeiros, L Jeffrey ^a   Young, Ken H ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Department of Medicine   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k San Bartolo Hospital   (Italy)

^l SAN RAFFAELE HOSPITAL   (Italy)

^m UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁿ HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^o AALBORG UNIVERSITY HOSPITAL   (Denmark)

^p ODENSE UNIVERSITY HOSPITAL   (Denmark)

^q TAIZHOU UNIVERSITY   (China)

^r UNIVERSITY OF HONG KONG   (Hong Kong)

^s RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^t University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RITUXIMAB; STAT3 PROTEIN; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADULT; ARTICLE; BCL2 GENE; BCL6 GENE; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; DEVELOPED COUNTRY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC DAMAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; MDM4 GENE; MULTICENTER STUDY (TOPIC); MUTATIONAL ANALYSIS; ONCOGENE MYC; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE; WESTERN HEMISPHERE; AGED; CANCER STAGING; CLUSTER ANALYSIS; COMPLICATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; STATISTICS AND NUMERICAL DATA; SURVIVAL; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD30; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLUSTER ANALYSIS; CYCLOPHOSPHAMIDE; DEVELOPED COUNTRIES; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; NF-KAPPA B; PHOSPHORYLATION; PREDNISONE; PREVALENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN; VINCRISTINE;

EID: 84899764939     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3157     Document Type: Article

References (44)

1. Nakamura S, Jaffe ES, Swerdlow SH, editors. EBV positive diffuse large B-cell lymphoma of the elderly. Lyon: International Agency for Research on Cancer; 2008.
2. Beltran BE, Morales D, Quinones P, Medeiros LJ, Miranda RN, Castillo JJ. EBV-positive diffuse large b-cell lymphoma in young immunocompetent individuals. Clin Lymphoma Myeloma Leuk 2011;11:512-6.
3. Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 2013;122:328-40.
4. Wada N, Ikeda J, Hori Y, Fujita S, Ogawa H, Soma T, et al. Epstein-Barr virus in diffuse large B-cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries. J Med Virol 2011;83:317-21.
5. Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007;110:972-8.
6. Hofscheier A, Ponciano A, Bonzheim I, Adam P, Lome-Maldonado C, Vela T, et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol 2011;24:1046-54.
7. Gibson SE, Hsi ED. Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol 2009;40:653-61.
8. Hoeller S, Tzankov A, Pileri SA, Went P, Dirnhofer S. Epstein-Barr viruspositive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 2010;41:352-7.
9. Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosia SG, Mazorra F, et al.EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol 2012;25:968-82.
10. Uner A, Akyurek N, Saglam A, Abdullazade S, Uzum N, Onder S, et al. The presence of Epstein-Barr virus (EBV) in diffuse large B-cell lymphomas (DLBCLs) in Turkey: special emphasis on 'EBV-positive DLBCL of the elderly'. APMIS 2011;119:309-16.
11. Beltran BE, Castillo JJ, Morales D, de Mendoza FH, Quinones P, Miranda RN, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol 2011;86:663-7.
12. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013;121:2715-24.
13. Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012;120:3986-96.
14. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Tzankov A, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the international DLBCL rituximab-CHOP consortium program study. Leukemia 2012;26:2103-13.
15. Liu WM, Li R, Sun JZ, Wang J, Tsai J, Wen W, et al. PQN and DQN: algorithms for expression microarrays. J Theor Biol 2006;243:273-8.
16. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-502.
17. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003; 100:9991-6.
18. Garattini E, Terao M. The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 2012;8:487-503.
19. Alzein N, Mueller M, van Deursen J, Ahlquist D, Witzig T, Molina J. Epigenetic silencing of the EYA-4 gene in non-Hodgkin's lymphoma (NHL). J Clin Oncol 2005;23:16s (suppl; abstract nr 9553).
20. WangZ, Luo F, Li L, Yang L,Hu D,MaX, et al. STAT3 activation induced by Epstein-Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 And ERK signaling. Eur J Cancer 2010;46:2996-3006.
21. O'Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000;177:99-111.
22. Nakayama EE, Hoshino Y, Xin X, Liu H, Goto M, Watanabe N, et al. Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol 2000;74:5452-9.
23. Nakayama EE, Meyer L, Iwamoto A, Persoz A, Nagai Y, Rouzioux C, et al. Protective effect of interleukin-4-589T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load. J Infect Dis 2002;185:1183-6.
24. Bracci PM, Skibola CF, Conde L, Halperin E, Lightfoot T, Smith A, et al. Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk Lymphoma 2010;51:497-506.
25. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res 2009;143:209-21.
26. McGeoch DJ, Gatherer D. Lineage structures in the genome sequences of three Epstein-Barr virus strains. Virology 2007;359:1-5.
27. Lung ML, Chang GC, Miller TR, Wara WM, Phillips TL. Genotypic analysis of Epstein-Barr virus isolates associated with nasopharyngeal carcinoma in Chinese immigrants to the United States. Int J Cancer 1994;59:743-6.
28. Liu Q, Han A, You S, Yang Q, Liang Y, Dong Y. The association of genomic variation of Epstein-Barr virus BamHI F fragment with the proliferation of nasopharyngeal carcinoma. APMIS 2010;118: 657-64.
29. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large Bcell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
30. Carbone A, Gaidano G, Gloghini A, Pastore C, Saglio G, Tirelli U, et al. BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. Am J Pathol 1997;150:155-65.
31. Martin-Perez D, Vargiu P, Montes-Moreno S, Leon EA, Rodriguez-Pinilla SM, Lisio LD, et al. Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma. Leukemia 2012;26: 180-3.
32. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-74.
33. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010;21:11-9.
34. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
35. Kung CP, Meckes DG Jr, Raab-Traub N. Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta. J Virol 2011;85:4399-408.
36. Muromoto R, Ikeda O, Okabe K, Togi S, Kamitani S, Fujimuro M, et al. Epstein-Barr virus-derived EBNA2 regulates STAT3 activation. Biochem Biophys Res Commun 2009;378:439-43.
37. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009;15:283-93.
38. Perepu U, Dogan A, Maurer M, Allmer C, Thompson C, Ansell S, et al. EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared with EBV (-) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec 8-11, Atlanta, GA. Washington, DC: ASH; 2012. Abstract nr 1604.
39. Ahn JS, Yang DH, Choi YD, Jung SH, Yhim HY, Kwak JY, et al. Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. Am J Hematol 2013;88:774-9.
40. Jacobsen ED, Advani RH, Oki Y, Sharman J, Horwitz SM, Forero-Torres A, et al.A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results. In: Proceedings of the 54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA. Washington, DC: ASH; 2012. Abstract nr 2746.
41. Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690-7.
42. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010;116:1515-23.
43. Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ, Mason NJ. NEMObinding domain peptide inhibits constitutive NF-kappaB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. Clin Cancer Res 2011;17:4661-71.
44. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008;111:3701-13.